Compare Verisign, Inc. (VRSN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Verisign, Inc. trades at $288.99 (market cap $26.00B), while State Street SPDR S&P Biotech ETF trades at $159.44. The key difference: Verisign, Inc. pays a 1.13% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Verisign, Inc. nearer its low. Which is the better fit depends on your goals.
| VRSN | XBI | |
|---|---|---|
Market Cap | $26.00B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $310.00 | $164.28 |
52-Week Low | $211.49 | $88.79 |
Enterprise Value | $27.31B | — |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $282.94, down 3.55% over the past day, with a mixed earnings history including a recent Q2 2026 EPS miss. The stock shows a bullish technical trend with strong moving averages, while fundamentals highlight robust profitability with a net income margin near 50% and revenue growth to $1.66B in 2025. Recent news emphasizes record domain registrations and the delegation of the .web domain, supporting growth outlook.
The outlook remains positive with a consensus price target of $320, reflecting 13% upside, driven by AI-fueled domain demand and pricing power. Risks include contract renewals and high debt levels, but analyst sentiment is bullish with 60% buy ratings. The stock presents a growth opportunity with manageable execution risks.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
